Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics

doi:10.3390/diagnostics10090656

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24721

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24721

Title:	Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics
Authors:	Hu, JC;Lin, CY;Wang, SS;Chiu, KY;Li, JR;Chen, CS;Hung, SC;Yang, CK;Ou, YC;Cheng, CL;Yang, SF
Keywords:	H19;prostate cancer;polymorphism;outcome
Date:	2020
Issue Date:	2022-08-09T08:06:56Z (UTC)
Publisher:	MDPI
Abstract:	Active surveillance is the preferred strategy for very low risk, low risk, and some favorable intermediate risk of prostate cancer. However, the current risk stratifications with initial prostate-specific antigen (iPSA) levels and Gleason scores at biopsy can underestimate the true oncologic threat. More precise predictors are required to avoid the overtreatment of prostate cancer. H19 single-nucleotide polymorphisms (SNPs) have been found to play crucial roles in numerous malignancies, but not yet in prostate cancer. This study assessed the clinicopathologic effects of H19 SNPs on prostate cancer to identify potential active surveillance candidates. A total of 579 patients with prostate cancer who underwent robot-assisted radical prostatectomy between 2012 and 2017 were recruited. The patients were grouped by iPSA levels, and five H19 SNPs were evaluated. Our results show that patients with an iPSA level of <= 7 ng/mL had increased an likelihood of having Gleason score and group grade upgrades after radical prostatectomy compared with patients with an iPSA level of >7 ng/mL. Moreover, patients with loci polymorphisms in either rs3024270 or rs3741219 had a significantly higher risk of perineural invasion (rs3024270: Odds ratio (OR) 2.76, 95% confidence interval (CI) 1.30-5.87,p=0.01; rs3741219: OR 2.30, 95% CI 1.17-4.54,p=0.018). In conclusion, our results suggested that H19 SNPs play a role in the perineural invasion of prostate cancer.
URI:	http://dx.doi.org/10.3390/diagnostics10090656 https://www.webofscience.com/wos/woscc/full-record/WOS:000579937400001 https://ir.csmu.edu.tw:8080/handle/310902500/24721
Relation:	DIAGNOSTICS ,2020 ,v10 ,issue 9
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	175	View/Open

Loading...